Toxoplasma Infections¶
Chapter 235 | Part 5: Infectious Diseases
KEY CLINICAL POINTS¶
- Toxoplasmosis is caused by Toxoplasma gondii, an obligate intracellular coccidian with two life stages: tachyzoites (acute phase) and bradyzoites (chronic cysts).
- Transmission occurs via oral ingestion of oocysts, tissue cysts in undercooked meat, or transplacental route. Immunocompromised hosts (e.g., HIV/AIDS, transplant recipients) are at risk for reactivation.
- Acute infection is often asymptomatic in immunocompetent individuals, but can cause lymphadenopathy, ocular disease, or encephalitis. Congenital infection may lead to chorioretinitis, hydrocephalus, and neurologic sequelae.
- Diagnosis involves serology (IgM/IgG), PCR, and imaging (MRI/CT). Treatment for immunocompromised patients includes pyrimethamine, sulfadiazine, and leucovorin. Prophylaxis with TMP-SMX is recommended for high-risk patients.
- Prevention focuses on avoiding undercooked meat, cat feces exposure, and proper food hygiene to reduce environmental contamination.
1. DEFINITION & OVERVIEW¶
Toxoplasmosis is caused by infection with Toxoplasma gondii, an obligate intracellular coccidian. Acute infection acquired after birth is typically asymptomatic, but some immunocompetent individuals may develop systemic or ocular disease. Chronic infection is characterized by tissue cysts containing bradyzoites, which persist in the CNS and muscle. Reactivation in immunocompromised hosts (e.g., HIV/AIDS, transplant recipients) leads to severe complications like encephalitis.
1.1 Life Cycle¶
The life cycle includes tachyzoites (acute phase) and bradyzoites (chronic cysts). Tachyzoites replicate in nucleated cells, while bradyzoites form cysts in tissues. Oocysts are excreted in cat feces and can survive in the environment for years.
1.2 Pathogenesis¶
Tachyzoites cause tissue damage and inflammation, while bradyzoites form cysts that persist in tissues. Immune responses (humoral and cell-mediated) control acute infection but fail in immunocompromised hosts, leading to progressive organ damage.
2. EPIDEMIOLOGY¶
Global seroprevalence ranges from 11% in the U.S. to 78% in Brazil. Risk factors include immunocompromised status, pregnancy, and exposure to contaminated soil/water. Congenital infection occurs in ~1/3 of pregnancies with maternal infection, with severity linked to gestational age at infection.
3. ETIOLOGY & PATHOPHYSIOLOGY¶
T. gondii is a coccidian parasite with two life stages: tachyzoites (acute) and bradyzoites (chronic). Transmission occurs via oocysts (cat feces) or tissue cysts in meat. Pathogenesis involves immune evasion, tissue damage, and cyst formation. Strains from South America are more virulent than those in the Northern Hemisphere.
3.1 Transmission Routes¶
Oral ingestion of oocysts (contaminated soil/water), undercooked meat (tissue cysts), or transplacental transmission. Blood transfusions and organ transplants can also transmit the parasite.
3.2 Immune Response¶
Humoral (IgG) and cell-mediated immunity control acute infection. CD8+ T cells and macrophages mediate clearance of tachyzoites, while bradyzoites persist in cysts. Immunocompromised hosts lack effective immune control.
4. CLINICAL FEATURES¶
Immunocompetent hosts: asymptomatic or lymphadenopathy, ocular toxoplasmosis. Immunocompromised hosts: encephalitis, pneumonitis, myocarditis, retinitis. Congenital infection: chorioretinitis, hydrocephalus, microcephaly, and neurologic sequelae.
4.1 Immunocompetent Patients¶
Acute infection is usually asymptomatic. Ocular toxoplasmosis (chorioretinitis) is common, often associated with foodborne outbreaks. Lymphadenopathy is a frequent presentation.
5. DIFFERENTIAL DIAGNOSIS¶
Differential diagnoses vary by clinical setting. For example, ocular toxoplasmosis must be differentiated from syphilis, CMV, herpes, and tuberculosis. CNS lesions in AIDS patients require distinction from lymphoma, cryptococcal meningitis, and progressive multifocal leukoencephalopathy.
Table 235-1 Differential Laboratory Diagnosis of Toxoplasmosis¶
| CLINICAL SETTING | ALTERNATIVE DIAGNOSIS | DISTINGUISHING CHARACTERISTICS |
|---|---|---|
| Mononucleosis syndrome | Epstein-Barr virus infection | Serology/PCR |
| Mononucleosis syndrome | Cytomegalovirus infection | PCR/viral load/serology |
| Mononucleosis syndrome | HIV infection | Serology/antigen/viral load |
| Chorioretinitis in immunocompetent individual | Tuberculosis | Bacterial culture/PCR |
| ChoriRETINITIS in immunocompetent individual | Syphilis | Serology |
| Chorioretinitis in immunocompetent individual | Histoplasmosis | Serology/culture/antigen |
| CNS lesions in AIDS patient | Lymphoma or metastatic tumor | Tissue biopsy |
| CNS lesions in AIDS patient | Brain abscess | Culture/biopsy |
| CLINICAL SETTING | ALTERNATIVE DIAGNOSIS | DISTINGUISHING CHARACTERISTICS |
|---|---|---|
| CNS lesions in AIDS patient | Progressive multifocal leukoencephalopathy | PCR for JC virus |
| CNS lesions in AIDS patient | Fungal infection | Antigen/PCR/biopsy/culture |
| CNS lesions in AIDS patient | Mycobacterial infection | PCR/biopsy/culture |
6. INVESTIGATIONS & DIAGNOSIS¶
Diagnosis involves serology (IgM/IgG), PCR for DNA detection, and imaging (MRI/CT). CSF analysis may show pleocytosis and elevated protein. Molecular diagnostics (PCR, next-gen sequencing) are critical for immunocompromised patients.
6.1 Serology¶
IgM indicates acute infection; IgG reflects past exposure. IgA is more specific for congenital infection. Sabin-Feldman dye test and ELISA are used for antibody detection.
6.2 PCR and Imaging¶
PCR detects T. gondii DNA in CSF, blood, or ocular fluid. MRI/CT identify CNS lesions, with MRI being more sensitive for detecting brain involvement.
7. MANAGEMENT & TREATMENT¶
Immunocompetent patients: symptomatic treatment for ocular disease (pyrimethamine/sulfadiazine). Immunocompromised patients: pyrimethamine, sulfadiazine, and leucovorin. Prophylaxis with TMP-SMX, dapsone, or atovaquone is recommended for high-risk patients. Congenital infection requires spiramycin and pyrimethamine/sulfadiazine for 1 year.
7.1 Acute Infection¶
Immunocompetent patients: pyrimethamine (50 mg/d) + sulfadiazine (1000 mg qid) + leucovorin (10–25 mg/d). Alternatives: clindamycin or TMP-SMX (5 mg/kg TMP, 25 mg/kg SMX bid).
7.2 Prophylaxis¶
TMP-SMX (1 double-strength tablet qd) for HIV patients with CD4+ <200/ µ L. Dapsone-pyrimethamine or atovaquone may be used for sulfa intolerance.
8. PROGNOSIS & COMPLICATIONS¶
Prognosis is generally favorable in immunocompetent hosts but severe in immunocompromised patients. Complications include vision loss, neurologic damage, and opportunistic infections. Congenital infection may lead to long-term neurodevelopmental disabilities.
8.1 Immunocompromised Patients¶
Untreated toxoplasmosis is rapidly fatal. Prophylaxis with TMP-SMX reduces mortality. Recurrence risk is high if CD4+ counts drop below 200/ µ L.
8.2 Congenital Infection¶
Long-term sequelae include chorioretinitis, hydrocephalus, and intellectual disability. Early treatment with pyrimethamine/sulfadiazine improves outcomes.
9. SPECIAL CONSIDERATIONS¶
Pregnant women: avoid undercooked meat and cat feces. HIV patients: prophylaxis with TMP-SMX. Pediatric patients: treatment with pyrimethamine/sulfadiazine for 1 year. Elderly: monitor for drug interactions and renal function.
9.1 Pregnancy¶
Avoid undercooked meat and cat feces. Spiramycin is preferred for acute infection. Termination may be considered for severe first-trimester infection.
9.2 Immunocompromised Hosts¶
Prophylaxis with TMP-SMX or dapsone. Monitor CD4+ counts and adjust therapy as needed.
10. KEY POINTS & CLINICAL PEARLS¶
Key points: T. gondii is transmitted via oocysts, meat, or transplacental route. Acute infection is asymptomatic in immunocompetent hosts. Prophylaxis with TMP-SMX is critical for HIV patients. Ocular toxoplasmosis requires prompt treatment to prevent vision loss. Prevention includes food safety and cat hygiene.